Insider Transactions in Q2 2024 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
273
-3.51%
|
$37,128
$136.55 P/Share
|
|
May 31
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
273
+3.39%
|
$21,567
$79.02 P/Share
|
|
May 29
2024
|
Stephen A Sherwin Director |
SELL
Open market or private sale
|
Direct |
40,000
-42.34%
|
$5,320,000
$133.47 P/Share
|
|
May 29
2024
|
Stephen A Sherwin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+29.61%
|
$1,800,000
$45.32 P/Share
|
|
May 17
2024
|
Shalini Sharp Director |
SELL
Open market or private sale
|
Direct |
1,106
-52.67%
|
$155,946
$141.9 P/Share
|
|
May 17
2024
|
Shalini Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+50.0%
|
-
|
|
May 17
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
2,100
-6.23%
|
$296,100
$141.84 P/Share
|
|
May 17
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,199
+11.08%
|
-
|
|
May 17
2024
|
George J Morrow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,199
+50.0%
|
-
|
|
May 17
2024
|
Leslie V Norwalk Director |
SELL
Open market or private sale
|
Direct |
1,106
-52.67%
|
$155,946
$141.82 P/Share
|
|
May 17
2024
|
Leslie V Norwalk Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+50.0%
|
-
|
|
May 17
2024
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+1.73%
|
-
|
|
May 17
2024
|
Stephen A Sherwin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,199
+13.68%
|
-
|
|
May 17
2024
|
Johanna Mercier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+50.0%
|
-
|
|
May 15
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-32.24%
|
$2,100,000
$140.24 P/Share
|
|
May 15
2024
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.38%
|
$1,095,000
$73.6 P/Share
|
|
May 14
2024
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
12,500
-9.66%
|
$1,687,500
$135.63 P/Share
|
|
May 14
2024
|
Gary A Lyons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+8.81%
|
$525,000
$42.76 P/Share
|
|
May 14
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-32.24%
|
$2,025,000
$135.66 P/Share
|
|
May 14
2024
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.38%
|
$1,095,000
$73.6 P/Share
|
|
May 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
273
-3.51%
|
$38,220
$140.55 P/Share
|
|
May 06
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
273
+3.39%
|
$21,567
$79.02 P/Share
|
|
Apr 15
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
19,818
-19.32%
|
$2,635,794
$133.36 P/Share
|
|
Apr 15
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,818
+16.09%
|
$1,605,258
$81.27 P/Share
|
|
Apr 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
272
-3.5%
|
$37,264
$137.3 P/Share
|
|
Apr 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
272
+3.38%
|
$21,488
$79.02 P/Share
|